Milestone Pharmaceuticals (MIST) Competitors $1.43 -0.02 (-1.38%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.46 +0.03 (+1.75%) As of 08/1/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIST vs. CADL, AURA, ABEO, PRTA, ATXS, ALT, AMRN, PVLA, RCKT, and IVAShould you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Candel Therapeutics (CADL), Aura Biosciences (AURA), Abeona Therapeutics (ABEO), Prothena (PRTA), Astria Therapeutics (ATXS), Altimmune (ALT), Amarin (AMRN), Palvella Therapeutics (PVLA), Rocket Pharmaceuticals (RCKT), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry. Milestone Pharmaceuticals vs. Its Competitors Candel Therapeutics Aura Biosciences Abeona Therapeutics Prothena Astria Therapeutics Altimmune Amarin Palvella Therapeutics Rocket Pharmaceuticals Inventiva Milestone Pharmaceuticals (NASDAQ:MIST) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Do analysts recommend MIST or CADL? Milestone Pharmaceuticals currently has a consensus target price of $7.00, indicating a potential upside of 389.51%. Candel Therapeutics has a consensus target price of $22.00, indicating a potential upside of 249.76%. Given Milestone Pharmaceuticals' higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Candel Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media favor MIST or CADL? In the previous week, Candel Therapeutics had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 2 mentions for Candel Therapeutics and 1 mentions for Milestone Pharmaceuticals. Candel Therapeutics' average media sentiment score of -0.50 beat Milestone Pharmaceuticals' score of -1.00 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Milestone Pharmaceuticals Negative Candel Therapeutics Negative Which has more volatility & risk, MIST or CADL? Milestone Pharmaceuticals has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.91, meaning that its stock price is 191% less volatile than the S&P 500. Do insiders & institutionals believe in MIST or CADL? 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by company insiders. Comparatively, 16.6% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, MIST or CADL? Milestone Pharmaceuticals has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone Pharmaceuticals$1M76.45-$41.52M-$0.78-1.83Candel TherapeuticsN/AN/A-$55.18M-$1.34-4.69 Is MIST or CADL more profitable? Candel Therapeutics' return on equity of -136.74% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Milestone PharmaceuticalsN/A -329.85% -67.20% Candel Therapeutics N/A -136.74%-63.13% SummaryMilestone Pharmaceuticals beats Candel Therapeutics on 8 of the 15 factors compared between the two stocks. Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIST vs. The Competition Export to ExcelMetricMilestone PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.52M$2.99B$5.48B$9.53BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-1.8317.7428.8923.83Price / Sales76.45178.71371.1466.13Price / CashN/A41.9535.4557.96Price / Book5.728.508.265.54Net Income-$41.52M-$55.06M$3.25B$259.28M7 Day Performance-9.49%-3.99%-3.73%-4.67%1 Month Performance-25.52%9.58%4.28%4.37%1 Year Performance6.72%6.70%25.85%17.90% Milestone Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MISTMilestone Pharmaceuticals1.8266 of 5 stars$1.43-1.4%$7.00+389.5%+2.9%$77.52M$1M-1.8330Negative NewsUpcoming EarningsShort Interest ↑Gap DownCADLCandel Therapeutics2.1825 of 5 stars$6.57-2.5%$22.00+234.9%+13.5%$337.69M$120K-4.9060Gap DownAURAAura Biosciences1.5503 of 5 stars$6.77+0.9%$22.00+225.0%-31.6%$337.30MN/A-3.5650ABEOAbeona Therapeutics3.8493 of 5 stars$6.75+2.4%$19.25+185.2%+34.9%$337.12M$3.50M-5.3190News CoveragePRTAProthena3.2437 of 5 stars$6.29+0.5%$31.50+400.8%-69.5%$336.96M$135.16M-3.02130News CoveragePositive NewsUpcoming EarningsATXSAstria Therapeutics2.3924 of 5 stars$6.26+4.9%$30.00+379.2%-41.4%$336.91MN/A-3.3530News CoverageALTAltimmune2.2333 of 5 stars$4.05-0.7%$18.20+349.4%-40.7%$330.92M$20K-3.2150Upcoming EarningsAMRNAmarin0.5783 of 5 stars$15.55-1.7%$12.00-22.8%+22.0%$327.58M$228.61M-4.27360News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionPVLAPalvella Therapeutics2.6798 of 5 stars$31.00+5.0%$47.50+53.2%N/A$326.25M$42.81M-2.56N/AGap UpRCKTRocket Pharmaceuticals4.8342 of 5 stars$3.13+3.0%$18.60+494.2%-86.5%$324.63MN/A-1.19240Trending NewsUpcoming EarningsIVAInventiva2.5018 of 5 stars$3.21-5.3%$10.40+224.0%+42.5%$324.29M$9.95M0.00100News CoverageShort Interest ↑Gap Down Related Companies and Tools Related Companies CADL Alternatives AURA Alternatives ABEO Alternatives PRTA Alternatives ATXS Alternatives ALT Alternatives AMRN Alternatives PVLA Alternatives RCKT Alternatives IVA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIST) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredDon’t Touch Tesla Stock Without Reading This FirstJeff Brown says he wouldn’t touch Tesla stock right now—and the reason might shock you. A 40-year Wall Stre...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIST Stock Alerts